Sara Guillén-López

Prof. Sara Guillén-López

Lab de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatria, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2014 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva
MAM. Abreu‐González
M. Abreu‐González
AAAriadna González-del Angel
Ariadna González-del Angel
IGIsabel Ibarra González
Isabel Ibarra González
CFC. Fernández‐Lainez
C. Fernández‐Lainez
MOMiguel Angel Alcántara Ortigoza
Miguel Angel Alcántara Ortigoza

1 May 2014 in Anales de Pediatría
Verified
Journal Article
Closed access
IGIsabel Ibarra González
Isabel Ibarra González
CFC. Fernández-Lainez
C. Fernández-Lainez
LBLETICIA BELMONT-MARTINEZ
LETICIA BELMONT-MARTINEZ
SGSara Guillén-López
Sara Guillén-López
SMS. Monroy-Santoyo
S. Monroy-Santoyo
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva

Verified
Journal Article
Open access
PDF file
IGIsabel Ibarra González
Isabel Ibarra González
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva
SGSara Guillén-López
Sara Guillén-López
LBLETICIA BELMONT-MARTINEZ
LETICIA BELMONT-MARTINEZ
NGNidia Alejandra Guillén-Zaragoza
Nidia Alejandra Guillén-Zaragoza
Advances in an early diagnosis by expanded newborn screening (NBS) have been achieved mainly in developed countries, while populations of middle- and low-income countries have poor access, leading to disparities. Expanded NBS in Mexico is not mandatory. Herein, we present an overview of the differences and unmet NBS needs of a group of Mexican patients with inborn errors of intermediary metabolism (IEiM), emphasizing the odyssey experienced to reach a diagnosis. We conducted a retrospective observational study of a historical cohort of patients with IEiM from a national reference center. A total of 924 patients with IEiM were included. Although 72.5% of the diseases identified are detectable by expanded NBS, only 35.4% of the patients were screened. The mortality in the unscreened group was almost two-fold higher than that in the screened group. Patients experienced a median diagnostic delay of 4 months, which is unacceptably long considering that to prevent disability and death, these disorders must be treated in the first days of life. Patients had to travel long distances to our reference center, contributing to their unacceptable diagnostic odyssey. This study highlights the urgent need to have an updated, expanded NBS program with adequate follow up in Mexico and promote the creation of regional medical care centers. We also provide compelling evidence that could prove valuable to decision makers overseeing public health initiatives for individuals impacted by IEiM from middle- and low-income countries.

29 July 2017
Verified
Book Chapter
Closed access
PDF file
IGIsabel Ibarra González
Isabel Ibarra González
CRCecilia Ridaura-Sanz
Cecilia Ridaura-Sanz
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
SGSara Guillén-López
Sara Guillén-López
LBLETICIA BELMONT-MARTINEZ
LETICIA BELMONT-MARTINEZ
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva

29 July 2016 in Journal of Inborn Errors of Metabolism and Screening
Verified
Journal Article
Open access
SGSara Guillén-López
Sara Guillén-López
LMLizbeth López Mejía
Lizbeth López Mejía
IIIbarra-González Isabel
Ibarra-González Isabel
VMVela-Amieva Marcela
Vela-Amieva Marcela
Phenylketonuria (PKU) is caused by a deficient activity of enzyme phenylalanine (Phe) hydroxylase, which results in high Phe blood concentration, which is toxic to the central nervous system. The fundamental purpose of nutritional treatment is to reduce and maintain blood Phe between 2 mg/dL (120 µmol/L) and 6 mg/dL (360 µmol/L) in order to prevent neuropathogenic complications. At the same time, nutrition support must provide enough energy and nutrients to promote normal growth and development and also to avoid vitamin and mineral deficiencies. Phenylketonuria treatment must be maintained long-life and its adherence must be frequently assessed. The amount of Phe required by patients with PKU varies throughout life and must be adjusted according to individual tolerance, residual phenylalanine hydroxylase enzymatic activity, age, sex, growth rate, protein intake, and nutritional and biochemical status among others. Treatment must be done by trained personnel. It is necessary to unify treatment criteria and further research must be done.

23 October 2021 in Genes
Verified
Journal Article
Open access
PDF file
Marcela Vela-AmievaMarcela Vela-Amieva
Marcela Vela-Amieva
MOMiguel Angel Alcántara Ortigoza
Miguel Angel Alcántara Ortigoza
IGIsabel Ibarra González
Isabel Ibarra González
AAAriadna González-del Angel
Ariadna González-del Angel
LFLiliana Fernández-Hernández
Liliana Fernández-Hernández
Cynthia Fernandez-LainezCynthia Fernandez-Lainez
Cynthia Fernandez-Lainez
Establishing the genotypes of patients with hyperphenylalaninemia (HPA)/phenylketonuria (PKU, MIM#261600) has been considered a cornerstone for rational medical management. However, knowledge of the phenylalanine hydroxylase gene (PAH) mutational spectrum in Latin American populations is still limited. Herein, we aim to update the mutational PAH spectrum in the largest cohort of HPA/PKU Mexican patients (N = 124) reported to date. The biallelic PAH genotype was investigated by Sanger automated sequencing, and genotypes were correlated with documented biochemical phenotypes and theoretical tetrahydrobiopterin (BH4) responsiveness. Patients were biochemically classified as having classic PKU (50%, 62/124), mild PKU (20.2%, 25/124) and mild HPA (29.8%, 37/124). Furthermore, 78.2% of the included patients (97/124) were identified by newborn screening. A total of 60 different pathogenic variants were identified, including three novel ones (c. 23del, c. 625_626insC and c. 1315 + 5_1315 + 6insGTGTAACAG), the main categories being missense changes (58%, 35/60) and those affecting the catalytic domain (56.6%, 34/60), and c. 60 + 5G > T was the most frequent variant (14.5%, 36/248) mainly restricted (69.2%) to patients from the central and western parts of Mexico. These 60 types of variants constituted 100 different biallelic PAH genotypes, with the predominance of compound-heterozygous ones (96/124, 77%). The expected BH4 responsiveness based on the PAH genotype was estimated in 52% of patients (65/124), mainly due to the p. (Val388Met) (rs62516101) allele. Instead, our study identified 27 null variants with an allelic phenotype value of zero, with a predominance of c. 60 + 5G > T, which predicts the absence of BH4 responsiveness. An identical genotype reported in BIOPKUdb was found in 92/124 (74%) of our patients, leading to a genotype–phenotype concordance in 80/92 (86.9%) of them. The high number of variants found confirms the heterogeneous and complex mutational landscape of HPA/PKU in Mexico.